A Phase I Study of the Mitochondrial Metabolism Inhibitor CPI-613 for AML

Video

Timothy S. Pardee, MD, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).

Clinical Pearls

Timothy S. Pardee, MD, assistant professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).

  • 24 patients with relapsed or refractory AML received the mitochondrial metabolism inhibitor CPI-613 in combination with high-dose cytarabine and mitoxantrone.
  • The response rate was 54% (11 complete remissions + 2 complete remissions with incomplete count recovery).
  • Patients with poor risk cytogenetics tend to respond poorly to chemotherapy.
  • In this trial, the response rate of patients with poor risk cytogenetics was 53% (7/13).
Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content
Legislative Changes and Their Impact on Community Oncology Care

Legislative Changes and Their Impact on Community Oncology Care

April 24th 2024
Article

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

FDA Grants Ziftomenib Breakthrough Therapy Designation in NPM1-Mutant AML

FDA Grants Ziftomenib Breakthrough Therapy Designation in NPM1-Mutant AML

April 22nd 2024
Article

This breakthrough therapy designation of ziftomenib marks the first of its kinds in NPM1-mutant acute myeloid leukemia.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Real-World Analysis Shows Promising Outcomes, Safety With Ibrutinib in CLL

Real-World Analysis Shows Promising Outcomes, Safety With Ibrutinib in CLL

April 20th 2024
Article

A 2-year follow-up study showed that ibrutinib maintained efficacy and safety among patients with chronic lymphocytic leukemia, highlighting its importance in the field. 

Read More

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

April 15th 2024
Article

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

Read More